Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PANDORA trial: what clinicians have said so far
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- NCT04995016 ↗
- Unknown
- Tianjin Medical University Second Hospital
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PANDORA (pembrolizumab plus axitinib in locally advanced non-metastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PANDORA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma
- Interventions
- Pembrolizumab; Axitinib
- Arms
- Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma · Experimental
- Enrollment
- 18 (estimated)
- Primary outcomes
- Major Pathologic Response (MPR)
- Sponsor
- Tianjin Medical University Second Hospital
- Start
- Aug 20, 2021 (estimated)
- Primary completion
- Aug 20, 2022 (estimated)
- Results posted
- No
- Registry record
- NCT04995016 · updated Aug 6, 2021